Research ExplorerPublicationsCancer Suicide Gene Therapy with TK.007

Cancer Suicide Gene Therapy with TK.007

Standard

Cancer Suicide Gene Therapy with TK.007. / Hossain, Jubayer A; Riecken, Kristoffer; Miletic, Hrvoje; Fehse, Boris.

In: Methods Mol Biol, Vol. 1895, 2019, p. 11-26.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hossain, JA, Riecken, K, Miletic, H & Fehse, B 2019, 'Cancer Suicide Gene Therapy with TK.007', Methods Mol Biol, vol. 1895, pp. 11-26. https://doi.org/10.1007/978-1-4939-8922-5_2

APA

Hossain, J. A., Riecken, K., Miletic, H., & Fehse, B. (2019). Cancer Suicide Gene Therapy with TK.007. Methods Mol Biol, 1895, 11-26. https://doi.org/10.1007/978-1-4939-8922-5_2

Vancouver

Hossain JA, Riecken K, Miletic H, Fehse B. Cancer Suicide Gene Therapy with TK.007. Methods Mol Biol. 2019;1895:11-26. https://doi.org/10.1007/978-1-4939-8922-5_2

Bibtex

@article{a77f8e67458a478484859f1b7384fbcd,
title = "Cancer Suicide Gene Therapy with TK.007",
abstract = "Cancer is a devastating disease characterized by uncontrolled and aggressive cell growth. Suicide gene therapy (SGT) facilitating induction of malignancy-specific cell death represents a novel therapeutic approach to treat cancer, which has been investigated in several cancer types with very promising results. In addition, SGT has been suggested as a safeguard in adoptive immunotherapy and regenerative-medicine settings. Generally, SGT consists of two steps-vector-mediated delivery of suicide genes into tumors and subsequent activation of the suicide mechanism, e.g., by administration of a specific prodrug. This chapter provides a framework of protocols for basic and translational research using the Herpes-simplex-virus thymidine kinase (HSV-TK)/ganciclovir (GCV) system, the most widely used suicide gene approach. The protocols provide standard guidelines for the preparation of high-titer third-generation lentiviral vectors encoding a genetically improved HSV-TK version known as TK.007 and its application in in vitro and in vivo treatment setups.",
keywords = "Journal Article",
author = "Hossain, {Jubayer A} and Kristoffer Riecken and Hrvoje Miletic and Boris Fehse",
year = "2019",
doi = "10.1007/978-1-4939-8922-5_2",
language = "English",
volume = "1895",
pages = "11--26",
journal = "Methods Mol Biol",
issn = "1064-3745",
publisher = "Humana Press",

}

RIS

TY - JOUR

T1 - Cancer Suicide Gene Therapy with TK.007

AU - Hossain, Jubayer A

AU - Riecken, Kristoffer

AU - Miletic, Hrvoje

AU - Fehse, Boris

PY - 2019

Y1 - 2019

N2 - Cancer is a devastating disease characterized by uncontrolled and aggressive cell growth. Suicide gene therapy (SGT) facilitating induction of malignancy-specific cell death represents a novel therapeutic approach to treat cancer, which has been investigated in several cancer types with very promising results. In addition, SGT has been suggested as a safeguard in adoptive immunotherapy and regenerative-medicine settings. Generally, SGT consists of two steps-vector-mediated delivery of suicide genes into tumors and subsequent activation of the suicide mechanism, e.g., by administration of a specific prodrug. This chapter provides a framework of protocols for basic and translational research using the Herpes-simplex-virus thymidine kinase (HSV-TK)/ganciclovir (GCV) system, the most widely used suicide gene approach. The protocols provide standard guidelines for the preparation of high-titer third-generation lentiviral vectors encoding a genetically improved HSV-TK version known as TK.007 and its application in in vitro and in vivo treatment setups.

AB - Cancer is a devastating disease characterized by uncontrolled and aggressive cell growth. Suicide gene therapy (SGT) facilitating induction of malignancy-specific cell death represents a novel therapeutic approach to treat cancer, which has been investigated in several cancer types with very promising results. In addition, SGT has been suggested as a safeguard in adoptive immunotherapy and regenerative-medicine settings. Generally, SGT consists of two steps-vector-mediated delivery of suicide genes into tumors and subsequent activation of the suicide mechanism, e.g., by administration of a specific prodrug. This chapter provides a framework of protocols for basic and translational research using the Herpes-simplex-virus thymidine kinase (HSV-TK)/ganciclovir (GCV) system, the most widely used suicide gene approach. The protocols provide standard guidelines for the preparation of high-titer third-generation lentiviral vectors encoding a genetically improved HSV-TK version known as TK.007 and its application in in vitro and in vivo treatment setups.

KW - Journal Article

U2 - 10.1007/978-1-4939-8922-5_2

DO - 10.1007/978-1-4939-8922-5_2

M3 - SCORING: Journal article

C2 - 30539526

VL - 1895

SP - 11

EP - 26

JO - Methods Mol Biol

JF - Methods Mol Biol

SN - 1064-3745

ER -